A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Clinical trial NCT01441193 · TERMINATED

Trial details

NCT number

NCT01441193

Sponsor

Barbara Ensoli, MD

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2011-09-01

Primary completion

2014-02-01

Enrollment

11

View on ClinicalTrials.gov